Tanuxiciclib

• CAT Number: I045093
• CAS Number: 1983983-64-7
• Molecular Formula: C15H13FN6O
• Molecular Weight: 312.30
• Purity: ≥95%
• Synonyms: 6-(2-amino-3-fluoropyridin-4-yl)-2-(2-amino-6-methylpyrimidin-4-yl)pyridin-3-ol
• InChI: InChI=1S/C15H13FN6O/c1-7-6-10(22-15(18)20-7)13-11(23)3-2-9(21-13)8-4-5-19-14(17)12(8)16/h2-6,23H,1H3,(H2,17,19)(H2,18,20,22)
• InChIKey: UQHDKUFLWKTTDL-UHFFFAOYSA-N
• SMILES: CC1=CC(=NC(=N1)N)C2=C(C=CC(=N2)C3=C(C(=NC=C3)N)F)O

Tanuxiciclib（Cat No.:I045093）is an investigational oral cyclin-dependent kinase (CDK) inhibitor, primarily targeting CDK9, a key regulator of transcriptional elongation and cell survival. By inhibiting CDK9, Tanuxiciclib disrupts the expression of anti-apoptotic proteins like MCL-1, promoting cancer cell apoptosis. It is being studied in hematologic malignancies and solid tumors, especially those reliant on transcriptional addiction. Tanuxiciclib shows potential to overcome resistance to conventional therapies and may be used in combination regimens. Supplied for advanced oncology research focused on transcriptional regulation, apoptosis induction, and targeted cancer therapy development.